Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710358 · ClinicalTrials.gov registry record · Phase 3
A Study in Moderate to Severe Rheumatoid Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,307
- Enrollment target
NCT01710358 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,307 participants.
The verdict
NCT01710358, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,307 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to methotrexate (MTX) treatment.
Interventions
- DRUG Adalimumab
- DRUG Baricitinib
- DRUG Methotrexate
- DRUG Baricitinib Placebo
- DRUG Adalimumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,307 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710358
The ClinicalTrials.gov registry entry for NCT01710358 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Adalimumab is the first listed.
NCT01710358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710358 about?
NCT01710358 is a clinical study titled "A Study in Moderate to Severe Rheumatoid Arthritis". The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to methotrexate (MTX) treatment.
What is the current status of trial NCT01710358?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,307 participants. The study started on 2012-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01710358?
The interventions under investigation include: Adalimumab (DRUG), Baricitinib (DRUG), Methotrexate (DRUG), Baricitinib Placebo (DRUG), Adalimumab Placebo (DRUG).
Who is sponsoring clinical trial NCT01710358?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.